Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
OLMA Olema Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: OLMA
Price (delayed)
$4.69
Market cap
$320.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.9
Enterprise value
$271.4M
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is
Highlights
OLMA's quick ratio has soared by 59% year-on-year and by 45% since the previous quarter
The debt has declined by 48% year-on-year and by 20% since the previous quarter
Olema Pharmaceuticals's equity has soared by 62% YoY but it has decreased by 6% from the previous quarter
Olema Pharmaceuticals's net income has decreased by 30% YoY
Key stats
What are the main financial stats of OLMA
Market
Valuations
Earnings
Shares outstanding
68.42M
Market cap
$320.9M
Enterprise value
$271.4M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.84
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$142.79M
Net income
-$128.89M
EBIT
-$128.89M
EBITDA
-$127.31M
Free cash flow
-$124.84M
Per share
Balance sheet
Liquidity
EPS
-$1.9
EPS diluted
-$1.9
Free cash flow per share
-$1.46
Book value per share
$5.61
Revenue per share
$0
TBVPS
$4.8
Total assets
$409.64M
Total liabilities
$26.19M
Debt
$1.15M
Equity
$383.45M
Working capital
$370.6M
Debt to equity
0
Current ratio
15.22
Quick ratio
15.07
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-38.3%
Return on equity
-42.3%
Return on invested capital
-52.4%
Return on capital employed
-33.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OLMA stock price
How has the Olema Pharmaceuticals stock price performed over time
Intraday
4.22%
1 week
0.43%
1 month
11.4%
1 year
-52.39%
YTD
-19.55%
QTD
24.73%
Financial performance
How have Olema Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$142.79M
Net income
-$128.89M
Gross margin
N/A
Net margin
N/A
Olema Pharmaceuticals's net income has decreased by 30% YoY
The operating income has decreased by 30% YoY
Price vs fundamentals
How does OLMA's price correlate with its fundamentals
Growth
What is Olema Pharmaceuticals's growth rate over time
Valuation
What is Olema Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OLMA's EPS is up by 14% QoQ and by 5% YoY
Olema Pharmaceuticals's equity has soared by 62% YoY but it has decreased by 6% from the previous quarter
OLMA's price to book (P/B) is 60% less than its 5-year quarterly average of 2.1 and 56% less than its last 4 quarters average of 1.9
Efficiency
How efficient is Olema Pharmaceuticals business performance
The return on invested capital has grown by 13% since the previous quarter and by 9% year-on-year
Olema Pharmaceuticals's ROE has increased by 12% from the previous quarter
The return on assets has grown by 11% since the previous quarter and by 2.5% year-on-year
Dividends
What is OLMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OLMA.
Financial health
How did Olema Pharmaceuticals financials performed over time
OLMA's quick ratio has soared by 59% year-on-year and by 45% since the previous quarter
OLMA's current ratio has surged by 58% year-on-year and by 45% since the previous quarter
The debt is 100% smaller than the equity
Olema Pharmaceuticals's debt to equity has shrunk by 100% YoY
Olema Pharmaceuticals's equity has soared by 62% YoY but it has decreased by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.